Global Cryptococcosis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Treatment Type;

Amphotericin B - Amphocin , Fungizone and Other, Flucytosine - Ancobon and Other, Fluconazole - Diflucan and Other, Others.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, Drug Store, Mail Order Pharmacies and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn125885718 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Cryptococcosis Market (USD Million), 2021 - 2031

In the year 2024, the Global Cryptococcosis Market was valued at USD 5,919.89 million. The size of this market is expected to increase to USD 7,903.07 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.2%.

Cryptococcosis often presents with chronic symptoms that develop gradually over several weeks. The disease primarily manifests as meningitis (brain infection) and pulmonary (lung) infection. The incidence of cryptococcosis has increased over time due to various factors, including the rising prevalence of AIDS and the prolonged use of immunosuppressive medications. Individuals with HIV/AIDS are particularly susceptible to cryptococcal infections. Annually, there are approximately 220,000 cases of cryptococcal meningitis among HIV/AIDS patients worldwide, resulting in nearly 181,000 deaths.

For diagnosing cryptococcosis, several methods are employed, such as cryptococcal antigen testing, chest x-rays, lumbar punctures, and urine tests. The global burden of HIV significantly contributes to the prevalence of cryptococcosis. According to HIV.gov, in 2020, there were about 38.4 million people living with HIV worldwide, including 36.7 million adults and 1.7 million children under 15 years of age. Notably, 54% of the HIV-positive population comprised women and girls. The high prevalence of HIV and AIDS, coupled with the increased risk of cryptococcal infections among these patients, underscores the critical need for effective diagnostic and therapeutic strategies to manage and mitigate the impact of this life-threatening fungal disease.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Treatment Type
    2. Market Snapshot, By Distribution Channel
    3. Market Snapshot, By Region
  4. Global Cryptococcosis Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising HIV/AIDS Cases
        2. Increasing Immunosuppressant Use
        3. Improved Diagnostics
      2. Restraints
        1. Limited Availability of Diagnostics
        2. High Cost of Treatment
      3. Opportunities
        1. Development of Point-of-Care Diagnostics
        2. Rising Awareness
        3. Focus on Preventative Measures
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Cryptococcosis Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Amphotericin B
        1. Amphocin
        2. Fungizone
        3. Other
      2. Flucytosine
        1. Ancobon
        2. Other
      3. Fluconazole
        1. Diflucan
        2. Other
    2. Global Cryptococcosis Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Drug Store
      4. Mail Order Pharmacies
      5. Others
    3. Global Cryptococcosis Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Bristol-Myers Squibb Company
      2. Janssen Biotech, Inc. (Johnson & Johnson)
      3. Abbott Laboratories
      4. Novartis AG
      5. Pfizer, Inc
      6. Valeant Pharmaceuticals, Inc
      7. Glenmark Pharmaceuticals
      8. Sigmapharm Laboratories LLC
  7. Analyst Views
  8. Future Outlook of the Market